Civilization Ventures is a venture capital firm focused on healthcare innovations. They back inspired founders solving essential problems in healthcare.

Civilization Ventures

At CV, we champion visionary founders tackling the most critical challenges in biology and healthcare. With a portfolio worth $9.7B, encompassing 64 companies and 9 successful exits, we provide the capital and resources necessary for innovators to thrive.

Pillo Health

Lemonaid Health

Rocket Pharmaceuticals

Singular Bio

We're humbled to announce the acquisition of Civilization Ventures portfolio company Fluent BioSciences Inc. by Illumina - our 10th exit in the fund!

Our thanks to the founders, executives and visionaries behind Fluent, including our co-investors at Samsara (Mike Dybbs) and Illumina VC (Wouter Meuleman): Sepehr Kiani, Kristina Fontanez, William (Bill) Hyun, Adam Abate, Brian McKernan, Gary Zweiger and many others. 

On a personal note, this marks my 3rd exit to Illumina as an investor/executive, and I'm humbled that our fund is able to play a role in building cutting-edge life sciences tools that are driving the future of biological innovation.

We are thrilled to announce the acquisition of our portfolio company, Fluent BioSciences Inc., by Illumina, marking the 10th exit for our fund.

Congratulations to the founders, executives and visionaries behind Fluent, including Sepehr Kiani and Brian McKernan.

🔈 CV Fireside Chat Series: Sourcing Innovation

We want to extend a heartfelt thank you to our speakers for the second installment of the "Sourcing Innovation" series, which focused on the journey of two CEOs who have successfully spun out their PhD projects.  

Shakked Halperin, PhD: CEO and Founder of Replace Therapeutics (Exited) and Rewrite Therapeutics (Exited), spun out of University of California, Berkeley

Marco Lobba, Ph.D.: CEO and Co-Founder of CatenaBio, spun out of University of California, Berkeley

In the Sourcing Innovation series, we aim to broaden the discussion around academic entrepreneurship by exploring the spin-out process from two crucial perspectives: the PIs who lay the groundwork and the PhD trainees-turned-CEOs who bring these innovations to market.

🇺🇸 Happy early 4th of July from our team at CV 🇺🇸 

If you are interested in learning more about the transformative potential of Generative AI in healthcare and life sciences, hear our founding GP Shahram Seyedin-Noor share his views as part of the Talk Gen AI panel at Swissnex below. 

#generativeai 

https://lnkd.in/gCmUzFgM

🔈 CV Fireside Chat Series: Sourcing Innovation

We want to extend a heartfelt thank you to our speakers for the first installment of the "Sourcing Innovation" series. This segment delves into the intricate process of spinning out technologies from academia, providing invaluable insights from our distinguished advisors:

Hani Goodarzi: Core Investigator Arc Institute, Associate Professor University of California, San Francisco

David Schaffer: Director Bakar Labs/QB3, Distinguished professor University of California, Berkeley

In the Sourcing Innovation series, we aim to broaden the discussion around academic entrepreneurship by exploring the spin-out process from two crucial perspectives: the PIs who lay the groundwork and the PhD trainees-turned-CEOs who bring these innovations to market.

CIVI

COM:CIVILIZATIONVENTURES

Civilization Ventures